Metabolic reprogramming: A novel therapeutic target in diabetic kidney disease.
Wang M, Pang Y, Guo Y, Tian L, Liu Y, Shen C, Liu M, Meng Y, Cai Z, Wang Y, Zhao W.
Wang M, et al. Among authors: tian l.
Front Pharmacol. 2022 Sep 2;13:970601. doi: 10.3389/fphar.2022.970601. eCollection 2022.
Front Pharmacol. 2022.
PMID: 36120335
Free PMC article.
Review.